Liver resection for HER2-enriched breast cancer metastasis: case report and review of the literature

Surgical Case Reports

Table 1 Prognostic factors of overall survival in patients after liver metastasectomy from breast cancer. (only multivariate Cox regression analyses)

Study	Hoffman¹⁰	Abott¹⁵	Walsum¹²	Zegarac¹³	Dittmar¹⁶	Weinrich⁹	Vertriest¹⁴
Number	41	86	32	32	34	21	27
Duration	1999–2008	1997–2010	1991–2011	2006–2009	1997–2010	2001–2007	1996–2013
Median overall survival (months)	58	57	55	37	36	53	116
5-year overall survival (%)	48.4		37		28	33	78
Median disease-free survival (months)	34	14.2	11	22.5
5-year disease-free survival (%)	31		19				36
Characteristics of primary BC
ER status		p = 0.009		p < 0.05
ER status		(pos)		(pos)
Lymph node status				p < 0.05
Lymph node status				(neg)
Tumor size				p < 0.05
Tumor size				(<3 cm)
Grading						p = 0.0059
Stage							p = 0.03
Stage							(Stages I–II)
Characteristics of LM and LM treatment
Age					p = 0.004
Age					(<50)
Period from BC to LM	p = 0.0097			p < 0.05
Period from BC to LM	(>24 months)			(>24 months)
Number of LM			p < 0.05	p < 0.01			p = 0.04
Number of LM			(1 vs >1)	(1 vs >1)			(1 vs >1)
HER2 status					p = 0.010
HER2 status					(pos)
Absence of extrahepatic tumor					p = 0.042
Response to preoperative chemotherapy		p = 0.003
Response to preoperative chemotherapy		(good response)
Resection margins	p = 0.0015
Resection margins	(R0 vs R1/2)

BC breast cancer, ER estrogen receptor, LM liver metastasis, HER2 human epidermal growth factor receptor 2, neg negative, pos positive, R0 complete microscopic resection, R1 microscopic residual disease, R2 macroscopic residual hepatic or extrahepatic disease